Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma

NCT00563147 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00563147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00563147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
February 28, 2011
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma